Modality
Peptide
MOA
EGFRi
Target
SGLT2
Pathway
PI3K/AKT
Breast CaMigrainePompe
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Apr 2028
Phase 1Current
NCT03909247
1,144 pts·Pompe
2018-05→2028-04·Not yet recruiting
1,144 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-152.0y awayInterim· Pompe
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Not yet…
Catalysts
Interim
2028-04-15 · 2.0y away
Pompe
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03909247 | Phase 1 | Pompe | Not yet recr... | 1144 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 |